Facebook
Twitter
LinkedIn
Forward
Optimizing Solid Tumor Management with PARP Inhibition: Strategies for a Changing Paradigm
To register in advance click here: https://us06web.zoom.us/webinar/register/WN_jZkZhrIPQDmHdInMv53XCA
Activity attendees will gain an understanding of the role of the DNA damage response (DDR) pathway in solid tumor tumorigenesis and the latest guidelines and importance of genetic testing/counseling and related treatment recommendations; then they will be guided through an appraisal of current and emerging evidence for PARP inhibitors for solid tumor management. An expert-led discussion in transcending disparities in cancer care and improving equitable access will follow, as will a review of PARP inhibitor toxicity profiles and how to effectively anticipate, prevent, and manage adverse events that may arise. After the didactic portion of the presentation, an interactive case-based presentation will provide attendees an opportunity to apply what they have learned, with an emphasis on appropriate treatment selection, toxicity management, mitigation of modifiable health disparities, and promotion of patient adherence to oral oncolytic therapy.
Target Audience
Oncology, specialty, and managed care pharmacists and physicians attending the 2022 Academy of Managed Care Pharmacy (AMCP) Nexus Annual Meeting.
Learning Objectives
- Review emerging PARP inhibitor clinical trial data in both the treatment and maintenance settings for solid tumors, and discuss how these agents continue to galvanize change across the disease management continuum.
- Evaluate the crucial importance of genetic testing/counseling when considering PARP inhibitor therapy for patients with solid tumors.
- Appraise current expert consensus guideline recommendations for managing solid tumor malignancies with PARP inhibitors, including evidence-based approaches for anticipating, mitigating, and managing adverse events.
- Recognize healthcare disparities that result in inequitable access and identify approaches for overcoming these obstacles and improving outcomes for all patients.
- Use a case-based approach to develop practical strategies for appropriate treatment selection, toxicity management, mitigation of healthcare disparities and inequitable access to care, and promotion of patient adherence to PARP inhibitors and other oral oncolytics, with the express goal of improving outcomes across the solid tumor landscape.
Presented by Creative Educational Concepts, LLC
Supported through an independent educational grant from AstraZeneca and Merck.
Additional Information
| Attachment | Size |
|---|---|
 AMCP Nexus - PARP Pan Tumor Handout.pdf | 2.31 MB |
6:00-6:30 PM Registration and Buffet Dinner
6:30-6:40 PM Welcome and Introductions/Pre-test
6:40-7:00 PM State of the Science: Examining the Evolving PARP Inhibitor Evidentiary Base in Solid Tumors
7:00-7:25 PM The Role of PARPi in the Solid Tumor Paradigm: An Exploration of Current Guideline Recommendations and Future
Opportunities
7:25-7:45 PM Real-world Applications: Oncology Perspectives on Harnessing Efficacy and Embracing Equity
7:45-8:00 PM Conversations with the Experts/Audience Q&A/Post-test
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA (Activity Chair)
Director, Pharmacy Cancer Care
Assistant Professor of Pharmacy
Mayo Clinic
Rochester, MN
Patrick G. Pilié, MD
Assistant Professor, Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX
Farah Raheem, PharmD, BCOP
Clinical Pharmacy Specialist
Hematology/Oncology
Mayo Clinic Arizona
Phoenix, AZ
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Planners/Faculty:
Patrick G. Pilié, MD–disclosures to come.
Farah Raheem, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA–has disclosed that he receives research support from AstraZeneca and Janssen. He is also on the speakers bureau for Pfizer and is an advisor or consultant to Pi Health.
Peer Reviewer:
Katherine Lee, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
CEC Staff/Planners:
Tina Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy (ACPE)
This application-based activity is approved for 1.5 contact hour (.15 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-014-L01-P)
Upon completion of a CE request form, statements of credit will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
Available Credit
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation